APOC3 and inflammatory bowel disease: Statin use has been shown to reduce new-onset IBD risk in several studies [8, 9]; in addition, targets other than LPL [10], PCSK9 [11, 12] and APOC3 [13] for lipid-lowering drugs, have been found to be altered in IBD patients.